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Abstract
Background: Metabolic syndrome (MetS) has been identified as a major contributor to the development of
cardiovascular disease (CVD). Current recommendations for dietary management of people with MetS involve
quantitative and qualitative modifications of food intake, such as high consumption of vegetables, fruits, and whole
grain foods. The results from our previous human trials revealed the potential of the dietary components high-oleic
acid canola oil (HOCO)-docosahexaenoic acid (DHA) and high molecular weight barley β-glucan individually in
managing CVD risk factors. Foods with a combination of HOCO-DHA and barley β-glucan have never been tested
for their effects on CVD risk. The objective is to determine the effects of consuming novel foods HOCO-DHA, and
barley β-glucan on managing CVD risk factors in people with MetS.
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Methods/Design: We are conducting a randomized, single-blind crossover trial with four treatment phases of
28 days each separated by a 4-week washout interval. Participants (n=35) will be provided with weight-maintaining,
healthy balanced diet recommendations according to their energy requirements during the intervention periods.
Participants will receive muffins and cookies as treatment foods in a random order and will consume at least one
meal per day at the research center under supervision. The four treatments include muffins and cookies consisting
of (1) all-purpose flour and HOCO-DHA (50 g/day); (2) barley flour (4.36 g/day of β-glucan) and a blend of sunflower
oil, safflower oil, and butter as control oil (50 g/day); (3) barley flour (4.36 g/day of β-glucan) and HOCO-DHA (50 g/
day; dosage of DHA would be 3 g/day); and (4) all-purpose flour and control oil (50 g/day). At the beginning and
end of each phase, we will evaluate anthropometrics; systolic and diastolic blood pressure; blood lipid profile;
low-density lipoprotein subfractions and particle size; 10-year Framingham CVD risk score; inflammatory status;
and plasma and red blood cell fatty acid profiles, fecal microbiome, and body composition by dual-energy X-ray
absorptiometry.
Conclusion: Cholesterol synthesis will also be studied, using a stable isotope approach. The proposed study will lead
to innovation of novel food products, which may result in improvement in the overall cardiovascular health of humans.
Trial registration: Clinical trials.gov identifier: NCT02091583. Date of registration: 12 March 2014.
Keywords: Canola oil, Barley, β-glucan, DHA, Fiber, Cardiovascular disease, Metabolic syndrome, CONFIDENCE trial
Background
Metabolic syndrome (MetS), comprising a spectrum
of chronic disease risk factors that include abdominal
obesity, dyslipidemia, hypertension, and elevated fast-
ing plasma glucose, has been identified as a major
contributor to the development of cardiovascular dis-
ease (CVD) [1, 2]. In North America, 34 % of the adult
population are affected by MetS, and MetS occurrence is
even higher in other parts of the world [3]. Accordingly,
MetS has become a significant public health concern and
a burden on the global health care system, as this disorder
is associated with increased morbidity, mortality, and re-
lated health care costs.
Current recommendations for dietary management in
people with high risk for MetS involve quantitative and
qualitative modifications in food intake, such as higher
consumption of vegetables, fruits and whole grain food
components with their inherent bioactive composition.
More specifically, the presence of Mediterranean dietary
components [4, 5], amounts of long chain n-3 fatty acids
[6, 7], types and amounts of carbohydrates and dietary
fiber content, are some dietary elements reported to show
remarkable positive effects in the management of MetS.
Important components include high-oleic acid canola oil
(HOCO), barley β-glucan, docosahexaenoic acid (DHA).
Canola oil is derived from canola seed, which is ob-
tained from a bright yellow flowering plant belonging to
the Brassicaceae family [8]. Canola oil is considered the
third-largest vegetable oil by sales volume after palm
and soybean oil [9]. Canola’s nutritional profile includes
a low level (7 %) of saturated fatty acids; significant
amounts of monounsaturated fatty acids (MUFAs) and
polyunsaturated fatty acids (PUFAs), with 61 % oleic
acid, 21 % linoleic acid, and 11 % α-linolenic acid [10];
plant sterols (PSs) (0.53–0.97 %); and tocopherols (700–
1200 ppm) [8]. Canola oil has proven efficacy in prevent-
ing and/or managing chronic ailments, including dyslipid-
emia, insulin resistance, and inflammation [11, 12]. As a
result, in 2006, the U.S. Food and Drug Administration
(FDA) approved a qualified health claim for canola oil
suggesting that canola oil may help reduce the risk of
CVD when substituted for saturated fat in the diet [8].
MUFAs, one of the components of canola oil, help
reduce CVD risk by lowering blood pressure, blood
total cholesterol (TC), and low-density lipoprotein
cholesterol (LDL-C) levels; inhibiting LDL-C oxidation
[13–16]; and improving glycemic control [17–19]. Oleic
acid–enriched canola oil was developed to enhance the
health benefits of canola oil related to CVD risk reduc-
tion. Its health benefits were compared with regular can-
ola oil in humans in a randomized crossover human trial
[12]. In that trial, consumption of HOCO for 28 days
was shown to lead to reductions in TC and LDL-C levels
and LDL-C/high-density lipoprotein cholesterol (HDL-
C) values, as compared with regular canola oil and a
control diet without HOCO [12]. The results of a re-
cently completed multicenter randomized controlled
trial done at our laboratory validated these findings. In
that study, the serum triglycerides (TGs) and 10-year Fra-
mingham risk scores, TC/HDL-C and TG/HDL-C ratios,
and systolic blood pressure were significantly reduced, and
HDL was increased, after consumption of HOCO-DHA
compared with regular canola and control diets [20–23].
Consumption of fiber has been indicated to reduce the
mortality rate in high-risk CVD populations [24]. β-glucan
is a polysaccharide found mainly in yeast, mushrooms,
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oats, and barley in the form of fiber [25]. β-glucan fibers
are located mainly in the endosperm cell walls of cereals.
Among cereals, barley and oats are the richest sources of
β-glucan, containing 4.0–7.0 % and 2.2–7.8 % wt/wt of β-
glucan, respectively, compared with other cereals, such as
rye and wheat [26]. Similarly to canola oil, β-glucan has
gained significant attention among nutritional researchers
because it has been shown to have potentially health-
promoting effects in animal and human studies [25, 27].
Consequently, in 1997, the FDA approved a health claim
regarding β-glucan from whole oats for reducing the risk
of heart disease [28, 29]. More recently, the European
Food Safety Authority and Health Canada approved simi-
lar health claims for foods containing oats or barley β-
glucan [30, 31].
In agreement with the previous studies, we also dem-
onstrated the beneficial effects of high molecular weight
β-glucan in healthy adults in a recent randomized,
controlled-diet, crossover trial (n = 35). The results
showed that consumption of 3 g or 5 g per day of high
molecular weight barley β-glucan is highly effective in
reducing TC and LDL cholesterol in adults with moder-
ate hypercholesterolemia [32].
Long-chain PUFAs such as eicosapentaenoic acid
(EPA) and DHA from fish and marine source oils, in-
cluding algal oil, have commercially emerged as dietary
supplements due to their health benefits. Long-chain
fatty acids, including DHA, were shown to lower TG
and increase serum HDL-C concentrations [33]. DHA is
also capable of acting as an antiatherogenic factor by
inhibiting inflammatory processes and thereby inhibiting
plaque formation [34]. On the basis of the vast amount
of knowledge accumulated over the years, the American
Heart Association has recommended the use of n-3 fatty
acids, including DHA, for secondary prevention of car-
diovascular events in people with documented coronary
artery disease.
Considering the fact that CVD is a multifactorial
disease, the dietary approaches that combine different
bioactives with enhanced health benefits have recently
been well elucidated. For instance, a portfolio con-
taining a low-fat vegetarian diet enriched by the in-
clusion of PSs, soy protein, viscous fiber, and tree
nuts has been shown through our collaborations to
markedly reduce LDL-C concentrations to an extent
comparable in magnitude with reductions achieved
using first-generation statins [35, 36]. Likewise, a large
body of research has demonstrated the synergetic
effects attained by introducing two or more food
bioactive components into the diet to achieve max-
imal health benefits through multimechanistic effects
[37–39]. Accordingly, combining highly bioactive compo-
nents such as HOCO, barley β-glucan, and DHA is
expected to produce great synergistic and pleotropic
beneficial effects on CVD risks factors compared with the
individual biological actions listed above.
The overall objective of the present study is to test
novel foods containing the most effective bioactives,
including n-3 fatty acid–enriched dietary oil high in
MUFAs and soluble dietary fiber, with aims of managing
CVD risk factors in people with MetS and testing the
efficacy and safety of these dietary components in
humans.
Methods/Design
Design of the human intervention trial
A randomized, single-blind, crossover trial will be con-
ducted at the Clinical Nutrition Research Unit at the
Richardson Centre for Functional Foods and Nutraceuti-
cals (RCFFN), University of Manitoba, Winnipeg, MB,
Canada. The study design will consist of four phases
with 28 days per phase, and each phase will be separated
by 4-week washout periods (Fig. 1). Participants will
consume at least one of three daily meals under supervi-
sion, along with the treatment foods during weekdays
from days 2 to 29 of each phase. Treatment muffins and
cookies for the weekend will be packed and provided to
participants to take home on Fridays. The other meals will
be purchased by the participants from grocery stores on
their own. Almost half of the treatments will be consumed
under the supervision of a clinical coordinator to ensure
optimal compliance. Participants will be instructed to con-
sume no alcoholic or caffeinated beverages. Participants
will be instructed not to consume more than one serving
of fish or seafood products per month during the study. A
3-day food record will be collected before the study and
after each treatment phase. Participants will be strongly
recommended to maintain consistency in their physical
activities during the experimental period. Compliance
with the treatment products will be determined from
checklists and by measuring the amount of leftover food if
any in the containers returned by the participants the fol-
lowing day.
Diets will be planned for every participant according
to individual energy requirements and will be nutrition-
ally adequate. Basal energy requirement will be esti-
mated using the Mifflin-St Jeor equation [40]. The basal
energy requirements will be multiplied by an activity fac-
tor of 1.7 to supply the additional energy needs of mildly
to moderately active healthy adults. During the study
period, body weight will be monitored. If any of the par-
ticipants gain or lose weight during the first week,
adjustments to their estimated energy requirements will
be made. Participants will be given recommendations to
follow a typical Western diet that meets the Canadian
Dietary reference intake. The nutrient content of the
participant’s diet, based on the 3-day food record, will
be analyzed using Food Processor Nutrition Analysis
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software (ESHA Research, Salem, OR, USA) to ensure
the intake of macro- and micronutrients and compliance
with the protocol. Treatments will be isocalorically in-
corporated into muffins and cookies and consumed at
breakfast, in the evening, as snacks, and with supper.
Recruited participants will be randomly assigned to one
of the treatment sequences using a Latin square design.
Participants will be required to consume one muffin
along with their breakfast and two cookies during their
evening snack and dinner, respectively.
The four treatments are as follows: (1) muffins and
cookies containing all-purpose flour and 50 g/day
HOCO-DHA (85 %/15 %; DHA oil consists of 40 %
DHA) (DHA dosage 3 g/day); (2) muffins and cookies
containing barley flour with 4.36 g/day of high molecular
weight barley β-glucan and 50 g/day of a blend of sun-
flower oil, safflower oil, and butter as a control oil; (3)
muffins and cookies containing a combination of barley
flour with 4.36 g/day, high molecular weight barley β-
glucan, and 50 g/day of HOCO-DHA; and (4) muffins
and cookies containing all-purpose flour and 50 g/day of
control oil. The control oil used in the study represents
a typical Western diet fat intake as a control treatment
composed largely of saturated fat with substantial levels
of n-6 linoleic acid common in current North American
dietary intakes. Dosages for HOCO-DHA and barley β-
glucan were determined on the basis of previous clinical
studies done by our research group [20, 21, 32]. Muffin
and cookie recipes were developed in Agriculture and
Agri-Food Canada laboratories at the RCFFN metabolic
kitchen. Barley grain (cultivar CDC Rattan) was provided
by the Alberta Barley Commission and milled into whole
grain flour by the Canadian International Grains Insti-
tute. All-purpose flour was obtained from local super-
market. HOCO was provided by Richardson Oilseed
Limited. life’s DHA oil was purchased from DSM Nutri-
tional Products (Ayr, ON, Canada). Macronutrients, in-
cluding protein, carbohydrates, and fiber content of the
foods, were analyzed at the Agriculture and Agri-Food
Canada laboratories, RCFFN, Winnipeg, Canada. Total
fat and fatty acid profiles of the foods were measured at
the RCFFN laboratories (Winnipeg, MB, Canada). The
muffin flavors include vanilla and spice, and the cookies
were made in lemon, ginger, and chocolate flavors. The
flavors of the muffins and cookies will be provided in ro-
tation with equal numbers of days per flavor during each
treatment period. The nutrient compositions of the muf-
fins and cookies for the different treatments of the study
are depicted in Tables 1 and 2, respectively. The macro-
nutrient contents of treatment foods will be similar
between different treatments, and also there are no dif-
ferences in nutritional values between different flavors of
muffins or cookies.
Participant selection
Thirty-five male and female participants with MetS will
be enrolled in the study. They will be recruited using ad-
vertisements in local media, including newspapers, radio,
and the RCFFN official website, as well as on university
campuses. We will also recruit from our preexisting
database of participants. As well, to present information
about the nature of the study and procedures, sessions
will be held at the RCFFN during the recruitment
period, and potential study participants will be invited to
Fig. 1 Schematic representation of the experimental protocol. *Procedures are the same as in phase 1. Blood 12-h fasted blood collection, ANTH
anthropometric measurements, BP blood pressure, IE-CRIT inclusion and exclusion criteria, Qs questionnaires (fish and seafood consumption,
concomitant medications, adverse events, physical activity), 3D-FR 3-day food record collection, DEXA dual-energy X-ray absorptiometry, PHYS
physician examination, GI gastrointestinal questionnaires, STOOL stool sample collection, D2O deuterated water
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these sessions. Potential participants will undergo a
screening where blood pressure and anthropometric
measurements will be performed and 10-ml fasting
blood samples will be collected to test for lipid profiles.
Eligible participants will be asked to provide written in-
formed consent to participate in the study. The trial was
approved by the biomedical research ethics committee
at the University of Manitoba (B2014:029).
Inclusion criteria
Participants aged 18–70 years will be recruited. The par-
ticipants should be slightly overweight with a body mass
index >25 kg/m2 and waist circumference >94 cm for
men and >80 cm for women in accordance with the
International Diabetic Federation MetS criteria for
waist circumference. In addition, they have to be
deemed to be otherwise healthy by the study phys-
ician. Additionally, participants should also meet at
least two of the following criteria: (1) TG >1.7 mmol/
L, (2) HDL-C <1 mmol/L for males and <1.3 mmol/L
for females, (3) fasting glucose >5.6 mmol/L, (4) LDL-
C >2.7 mmol/L, and (5) blood pressure >130 mmHg for
systolic and >85 mmHg for diastolic.
Exclusion criteria
Participants taking lipid-lowering medications or nutri-
tional supplements known to affect blood lipids, or who
have any dietary restrictions that would prevent them
Table 1 Details and nutritional composition of the study muffins
Nutritional component measurements Control flour + HOCO-DHA Barley flour + control oil Barley flour + HOCO-DHA Control flour + control oil
Weight (g) 113 108 109 112
Energy (kcal/kJ)a 379/1586 383/1602 383/1602 379/1586
Total carbohydrates (g)a 33 36.59 36.59 32.65
Total proteins (g)a 8 9 9 8
Total fiber (g)a 0.36 5.77 5.77 0.36
β-glucan (g)a 0 2.18 2.18 0
Total fat (% weight) 24 23 23 23
SFA (%) 10.42 35.36 11.24 33.34
MUFA (%) 66.21 28.38 64.03 31.05
PUFA (%) 23.37 36.25 24.73 35.61
n-3 PUFA (%) 6.57 0.66 6.45 0.49
n-6 PUFA (%) 16.80 35.60 18.28 35.12
DHA docosahexaenoic acid, HOCO high-oleic acid canola oil, MUFA monounsaturated fatty acid, PUFA polyunsaturated fatty acid, SFA saturated fatty acid
aValues were calculated based on values of the ingredients. Muffins were made with two different flavors: vanilla and spice. Values presented are the average of
both the flavors, and there were no major differences between flavors for the measurements
Table 2 Details and nutritional composition of the study cookies
Nutritional component measurements Control flour + HOCO-DHA Barley flour + control oil Barley flour + HOCO-DHA Control flour + control oil
Weight (g) 52 50 52 53
Energy (kcal/kJ)a 213/891 221/924 221/924 213/891
Total carbohydrates (g)a 23 25 25 23
Total proteins (g)a 4 4 4 4
Total fiber (g)a 0.46 3.17 3.17 0.46
Beta glucan (g)a 0 1.09 1.09 0
Total fat (% weight) 24 24 23 24
SFA (%) 12.50 35.39 12.58 33.75
MUFA (%) 63.37 28.95 64.23 31.08
PUFA (%) 24.13 35.67 23.20 35.16
n-3 PUFA (%) 6.44 0.61 6.28 0.48
n-6 PUFA (%) 17.53 34.91 16.91 34.69
DHA docosahexaenoic acid, HOCO high-oleic acid canola oil, MUFA monounsaturated fatty acid, PUFA polyunsaturated fatty acid, SFA saturated fatty acid
aValues were calculated based on the values of the ingredients. Cookies were made with three different flavors: cocoa, ginger, and lemon. Values presented are
the average of the flavors, and there were no major differences between flavors for the measurements
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from consuming the study diet for 28 days during each
phase, will be excluded. Participants with a current or past
history of any diseases and disorders that could interfere
with fat absorption will be excluded. Individuals with
hypertension having systolic blood pressure >150 mmHg
or diastolic blood pressure >100 mmHg will be ex-
cluded from the study. Participants planning to become
pregnant during the study period will be excluded.
Smokers and people consuming more than one alco-
holic drink/day or who have a history of alcoholism or
drug dependence cannot be included in the study. Use
of any experimental medication within 1 month before
screening or as concomitant medication is also an
exclusion criterion.
Sample collection
Twelve-hour fasting blood samples will be collected on
days 1, 2, 29, and 30 of each intervention phase. Partici-
pants will be advised to be fasted for 12 h and not to
consume any alcoholic beverage for at least 48 h before
blood collection. Participants will also be instructed to
refrain from engaging in intense physical activity (aer-
obic, spinning, and running) for at least 24 h before each
visit. On days of blood collection, a checklist with ques-
tions on 12-h diet, 48-h alcohol, and 24-h physical activ-
ity will be administered and data recorded to determine
participant compliance.
Blood samples will be centrifuged at 3000 rpm for
20 minutes at 4 °C; aliquoted to yield serum, plasma,
and red blood cells (RBC); and then stored at −80 °C
until analyses. To obtain the plasma lipid profile,
average values of days 1 and 2 will be considered as
baseline and average values of days 29 and 30 will be
considered as the endpoint of each treatment phase.
In addition, the influence of these diets on gastro-
intestinal microbial diversity in the current study
population will be measured. For this analysis, stool
samples (four or five scoops totaling 4 g) will be col-
lected before and after each intervention phase (days
2 and 30) of the trial. Stool sample collection kits,
including containers, will be provided for the partici-
pants to collect their stool samples. However, it is
optional for the participants to provide the stool
samples, and they may still participate if they choose
not to provide stool samples.
Stable isotope tracer intake
To assess cholesterol fractional synthesis rate (FSR),
participants will be asked to consume deuterated
water (D2O) at the end of each phase. On day 29,
0.7 g of D2O per kilogram of estimated body water
will be given orally before breakfast as a tracer to
measure cholesterol FSR over 24 h. Fasting blood will
be obtained on days 29 and 30.
Clinical data collection
Whole-body dual-energy X-ray absorptiometry (DEXA)
(Prodigy Advance; GE Healthcare Lunar, Madison, WI,
USA) will be conducted to determine changes in body
fat composition during the last week of each phase.
Blood pressure, body weight, and waist circumference
will be monitored at the beginning and end of each
treatment period. An automated blood pressure device
will be used to measure blood pressure. Participants will
be advised to rest quietly throughout the measurements.
Blood pressure will be measured four times at 2-minute
intervals. The first measurement will be ignored, and the
last three measurements will be averaged to determine
systolic and diastolic blood pressures. Gastrointestinal
tolerability questionnaires will be completed by partici-
pants at the beginning and end of each intervention
period. The 10-year Framingham CVD risk score will be
calculated for each participant during each phase [41].
Analytical methodology
Plasma samples will be analyzed for total lipid profiles,
including TC, HDL-C, and TG levels, as well as for glu-
cose levels, using the automated enzymatic methods on
a VITROS 350 Chemistry System (Ortho Clinical Diag-
nostics, Markham, ON, Canada). LDL-C values will be
calculated using the Friedewald equation [42]. Subfrac-
tions and particle sizes of LDL-C after each treatment
intervention will be determined by the proprietary Lipo-
print Lipoprotein Subfractions Testing System (Quanti-
metrix, Redondo Beach, CA, USA).
Inflammatory markers such as plasma C-reactive pro-
tein and serum amyloid A levels will be measured with
commercially available enzyme-linked immunosorbent
assay (ELISA) kits. Plasma cytokines, specifically inter-
leukin (IL)-1, IL-6, IL-8, IL-10, and tumor necrosis
factor-α, will be measured by multiplex human ELISA.
Plasma soluble adhesion molecules such as soluble
vascular cell adhesion molecule 1, soluble intercellular
adhesion molecule 1, and soluble P-selectin and E-
selectin will also be measured with commercially avail-
able human ELISA kits. Apolipoproteins A1, B, and E
will be analyzed with commercially available ELISA
kits.
Fasting plasma insulin concentrations will be deter-
mined using an ELISA kit. Insulin homeostasis modeling
assessment will be used as an estimate for percentage β-
cell function and insulin resistance.
Plasma and red blood cell fatty acid analyses
Plasma and RBC total lipids will be extracted using the
Folch method [43], involving chloroform-methanol (2:1
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vol/vol) containing 0.01 % 3,5-di-tert-4-butylhydroxyto-
luene (Sigma-Aldrich, Oakville, ON, Canada) and hepta-
decanoic acid as an internal standard (Sigma-Aldrich).
Extracted fatty acids will be methylated with methanolic
HCl. Fatty acid methyl esters will be separated on a
SUPELCOWAX 10 capillary gas chromatography col-
umn (30 m × 0.25 mm with 0.25-mm film thickness;
Supelco/Sigma-Aldrich, Bellefonte, PA, USA) using a gas
chromatograph equipped with a flame ionization de-
tector (Bruker 430; Bruker Daltonics, Billerica, MA,
USA). Individual fatty acids will be identified by com-
parison with known standards (Nu-Chek Prep, Elysian,
MN, USA). Individual fatty acid levels will be calculated
according to the peak area relative to the total area and
expressed as a percentage of total fatty acids.
Concentrations of isotope-labeled cholesterol in cir-
culatory cholesterol will be measured over 24 h. In
this study, we will measure the deuterium enrichment
into RBC cholesterol to calculate FSR of whole-body
cholesterol. The initial 24-h interval of D2O uptake is
considered to be the optimal period for measuring
synthesis [44]. The analytical methods for isotope
analyses are as follows. For determining cholesterol
FSR (%/day), RBC from day 29 and 30 will be saponi-
fied with freshly prepared KOH-methanol at 100 °C for
1 h, and the sterol fraction will be extracted with petrol-
eum diethyl ether. RBC cholesterol deuterium enrichment
will be quantified using a gas chromatography-pyrolysis-
isotope ratio mass spectrometry (Delta V Pulse Isotope
Ratio Mass Spectrometer; Thermo Fisher Scientific, Bre-
men, Germany). Hydrogen gas reduced from water will
be analyzed for deuterium enrichment against Vienna
Standard Mean Ocean Water [45].
Microbiome analysis
Bacterial DNA from the fecal samples will be ex-
tracted using the ZR Fecal DNA MiniPrep kit (Zymo
Research, Irvine, CA, USA), and DNA concentration
and quality will be determined using a NanoDrop
2000c spectrophotometer (NanoDrop Products/
Thermo Fisher Scientific, Wilmington, DE, USA).
Gut microbial composition will be analyzed by next-
generation Illumina-based sequencing (Illumina, San
Diego, CA, USA). Briefly, the V3-V4 region of the
16S rRNA gene will be targeted for PCR amplifica-
tion as described by Fadrosh et al. [46]. PCR prod-
ucts will then be purified using ZR-96 DNA Clean-
up Kit (Zymo Research) and added to the MiSeq
Reagent Kit V3 (300 cycles; Illumina) for sequencing
reactions on a MiSeq platform. The paired-end Illu-
mina fastq files will then be analyzed using the
QIIME software package [47]. Principal coordinate
analysis will be performed to evaluate the distance
matrices by generating two-dimensional plots using
PRIMER v6 software (PRIMER-E, Ivybridge, UK).
Sample size calculation and statistical analysis
Sample size was determined to detect an anticipated
difference in LDL-C level of 7.4 % (0.43 mmol/L) due to
HOCO consumption, compared with control, with a
standard deviation estimate of 0.13 mmol/L. The α and
power were taken as 0.05 and 0.8, respectively. A sample
size of 35 participants was therefore calculated, with a
target of 28 participants, taking into account the block
size and the estimated 20 % premature withdrawal rate
of participants from the protocol, given the existing level
of difficulty in completing the protocol elements.
Statistical analysis will be performed using SAS statis-
tical software (SAS Institute, Cary, NC, USA). Baseline
and endpoint measurements will be compared using the
analysis of variance (ANOVA) model for determination
of treatment effects. The results will be expressed as
means with standard errors. The normality of distribu-
tion of data will be determined with the Shapiro–Wilk
test, and the non-normal variables will be normalized
before comparison with other treatment by log trans-
formation. The effects of dietary treatments will be ex-
amined using mixed-model ANOVA with diet, sequence,
phase, and center as fixed factors and subject as a ran-
dom factor within the model. Statistical significance will
be set at p < 0.05 for all analyses. Significance between
different dietary effects will be examined with the Bon-
ferroni adjustment for multiple comparisons.
Adverse events and concomitant medications
No adverse events due to the study treatments are ex-
pected, based on the previous studies [20] and because
the experimental components are foods. Adverse events,
if any, will be monitored and will be reported in the case
report form. All serious adverse events will be reported
to sponsors and the institutional ethics board of the
University of Manitoba. Serious adverse events will be
brought to the attention of the study physician immedi-
ately for assignment of attribution. All prescription and
over-the-counter medications either used at the start of
the trial or initiated during the trial will be recorded.
Conditions for withdrawal from the study
The following events are to be considered sufficient
reason for discontinuing a participant from the study:
poor compliance (consuming <70 % of the given
treatment foods and/or dietary guidelines) or non-
compliance by the participant; developing condition(s)
or consumption of fish, supplements, or medications
as specified under the exclusion criteria; and present-
ing with an adverse event or any other medical
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situation where continuation of the study’s treatment
would compromise the participant's health.
Confidentiality of data
All the data collected for this study will remain confi-
dential in accordance with the Personal Health Informa-
tion Act of Manitoba, as applicable. However, the
clinical research team members involved will know the
identity of the participants. The researchers may know
the identity of the participants if they are requested to
respond to questions during the informed consent
process. All research team members will respect the
concept of confidentiality at all times.
Each participant will be assigned a unique code so that
all personal information, including questionnaire infor-
mation, will be confidential. Full names and other identi-
fying information will not be revealed, unless required
by law and/or for the applicable research ethics board
review or for auditing purposes. The identity of the par-
ticipants will not be revealed in any published data or in
presentation of the information obtained as a result of
this study. Medical records containing the identity of the
participant will be treated as confidential.
Data handling and storage
All data collected will be collated and secured in a
locked filing cabinet in a locked office at the RCFFN and
made available only to the study investigators and study
coordinators for research purposes. The data will include
patient history information, which will be recorded when
enrolling the participants in the trial. The purpose of
accessing the data will be restricted to creation of final
results tables and statistical interpretation. The data will
not be used for any other purposes.
Participant feedback
The primary outcomes, including the 10-year Framing-
ham CVD risk score and blood lipid profile results, will
be given to the study participants when the analyses are
completed. Participants will receive a sealed and confi-
dential letter that states their individual results for the
parameters measured for study purposes, along with the
mean values obtained for the entire study population.
The letter will be sent by the principal investigator at
the RCFFN to the mailing address listed on the personal
information form that participants fill out before enroll-
ment in the study.
Discussion
Considering the huge health impact of dietary portfolio
intervention approaches as highly efficient nutritional
strategies for the modification of CVD risk factors, com-
bination of food components and bioactives are getting
tremendous attention as an alternative strategy to
manage CVD risk factors. We anticipate that, taken to-
gether, the foods containing both HOCO-DHA and
barley-derived high molecular weight β-glucan will pos-
sess a superior biological action due to their differential
mechanistic effects, compared with the individual com-
ponents, against CVD risk factors.
In the current proposal, combining these potent
groups of food bioactives, such as HOCO-DHA and
β-glucan, to achieve parallel multiplication of bio-
logical action and to reduce the CVD events substan-
tially is of paramount clinical significance. This study
will be the first investigation of the cholesterol-
lowering effect of a combination of HOCO-DHA and
barley β-glucan. The proposed study will help to im-
prove understanding of the metabolic mechanisms
underpinning the health benefits associated with con-
sumption of foods consisting of HOCO-DHA and
barley β-glucan. The proposed research will not only
support the improvement of the cardiovascular health
of Canadians but also increase the marketability of
our canola-barley products internationally. The antici-
pated outcomes of the proposed study are expected
to have a high probability of impacting the health and
wellness of Canadians because (1) a significant proportion
of the population has MetS and (2) scientific data gener-
ated by well-designed, unbiased human clinical trials are
required to properly substantiate health effects of a
combination of HOCO-DHA and barley β-glucan.
Trial status
The trial is registered at ClinicalTrials.gov (NCT02091583).
Muffins and cookies required for the study have been devel-
oped and analyzed for their nutritional content. The clinical
intervention of the study was initiated in January
2015, and recruitment and randomization of partici-
pants, along with the study dietary interventions, are
ongoing.
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